Xtacy Therapeutics Corp. Share Price Deutsche Boerse AG
Equities
TT5
CA98423G1072
Investment Management & Fund Operators
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.011 EUR | 0.00% | -45.00% | -12.00% |
Sales 2022 | - | Sales 2023 | - | Capitalization | 2.46M 2.28M 196M |
---|---|---|---|---|---|
Net income 2022 | -1M -926K -79.63M | Net income 2023 | - 0 0 | EV / Sales 2022 | - |
Net Debt 2022 | 25.37K 23.49K 2.02M | Net Debt 2023 | 16.7K 15.47K 1.33M | EV / Sales 2023 | - |
P/E ratio 2022 |
-3.97
x | P/E ratio 2023 |
-4.19
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.2% |
1 week | -45.00% | ||
Current month | -15.38% | ||
1 month | -18.52% | ||
3 months | -45.00% | ||
6 months | -73.81% | ||
Current year | -12.00% |
Managers | Title | Age | Since |
---|---|---|---|
Meris Kott
CEO | Chief Executive Officer | - | 29/11/17 |
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 09/04/19 |
Monita Faris
SEC | Corporate Secretary | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 09/04/19 |
Meris Kott
CEO | Chief Executive Officer | - | 29/11/17 |
Ashleigh Vogstad
BRD | Director/Board Member | - | 29/10/19 |
Date | Price | Change |
---|---|---|
13/05/24 | 0.011 | 0.00% |
10/05/24 | 0.011 | 0.00% |
09/05/24 | 0.011 | +4.76% |
08/05/24 | 0.0105 | -27.59% |
07/05/24 | 0.0145 | -27.50% |
Delayed Quote Deutsche Boerse AG, May 13, 2024 at 07:03 am
More quotes1st Jan change | Capi. | |
---|---|---|
-1.90% | 118B | |
+3.68% | 95.3B | |
+13.51% | 69.05B | |
+20.25% | 63.76B | |
+12.33% | 43.7B | |
+14.16% | 43.06B | |
+19.87% | 34.41B | |
+4.46% | 24.92B | |
-0.72% | 23.07B |
- Stock Market
- Equities
- XTCY Stock
- TT5 Stock